Skip to main content

Advertisement

SpringerLink
Log in

Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

There is evidence that rheumatoid arthritis (RA) is associated with higher overall and cardiovascular (CV) morbidity and mortality as compared with general population. Increased prevalence of traditional risk factors and chronic inflammation, that has been recognized as independent CV risk factor, may play an important role in atherosclerosis and subsequently ischemic heart disease development. However, myocardial dysfunction as a result of chronic inflammation and secondarily myocardial fibrosis markedly participates on heart failure development. Proinflammatory cytokines, such as C-reactive protein, tumor necrosis factor alpha (TNFα), interleukins 1 and 6, that are markedly increased in RA, play a role in the acceleration of atherosclerosis as well as myocardial fibrosis development. Several studies documented that increased CV risk was associated with seropositivity, disease activity score, citrullination, and duration of RA. Early detection of heart dysfunction is based on echocardiographic detection of diastolic dysfunction resulting from myocardial inflammation and fibrosis. Some studies showed also higher prevalence of left ventricular systolic dysfunction and increased prevalence of cardiac arrhythmias as compared to non-RA population. There are still controversies on the impact of NT-proBNP in predicting cardiac impairment in RA patients. Some authors consider it to be a sensitive noninvasive predictor of subclinical CV disease in these patients and also a predictor of all-cause mortality independently on traditional CV risk factors. However, the correlation with parameters of cardiac function was confirmed only in a few studies. The impact of biological treatment on progression of atherosclerosis and heart failure is still controversial and seems to be not harmful in young patients with normal left ventricular function. The effect of biologics, especially anti-TNFα drugs, is probably related to the cardiac function before treatment. Larger prospective clinical, echocardiographic, and magnetic resonance studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4(3):130–136

    Article  PubMed  Google Scholar 

  2. Norton S, Sacker A, Dixey J, Done J, Williams P, Young A (2013) Early rheumatoid arthritis study. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. Rheumatology (Oxford) 52(11):2016–2024

    Article  Google Scholar 

  3. Schuett KA, Lehrke M, Marx N, Burgmaier M (2015) High risk cardiovascular patients: clinical features, comorbidities and interconnecting mechanisms. Front Immunol 6:1–9

    Article  Google Scholar 

  4. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S et al (2007) Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatol (Oxford) 46(2):350–357

    Article  CAS  Google Scholar 

  5. Wallberg-Johnsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 24:445–451

    Google Scholar 

  6. Ajeganova S, Humphreys JH, Verheul MK, van Steenbergen HW, van Nies JA, Hafstrom I et al. (2016) Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but different cause of death in patients with rheumatoid arthritis: a longitudinal study in three European cohort. Ann Rheum Dis. doi: 10.1136/annrheumdis-2015-208579.

  7. Crepaldi G, Scire CA, Carrara G, Sakellariou G, Caporali R, Hmamouchi I et al (2016) Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. PLoS One 11(1):e0146991. doi:10.1371/journal.pone.0146991

    Article  PubMed  PubMed Central  Google Scholar 

  8. Innala L, Sjoberg C, Moller B, Ljung L, Smedby T, Sodergren A et al (2016) Co-morbidity in patients with early rheumatoid arthritis-inflammation matters. Arthritis Res Ther 18(1):33. doi:10.1186/s13075-016-0928-y

    Article  PubMed  PubMed Central  Google Scholar 

  9. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2004) Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatism 50:3450–3456

    Article  Google Scholar 

  10. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE (2005) Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis. Arthritis Rheum 52:402–410

    Article  PubMed  Google Scholar 

  11. Kobayashi H, Giles JT, Polak JF, Blumenthal RS, Leffell MS, Szklo M et al (2010) Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery specific. J Rheumatol 37:730–739

    Article  PubMed  Google Scholar 

  12. Giles JT, Fernandes V, Lima JAC, Bathon JM (2005) Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther 7:195–207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Matthews PM, Robson MD et al (2015) Diffuse myocardial fibrosis and inflammation in rheumatoid arthritis: insights from CMR T1 mapping. JACC Cardiovasc Imaging 8(5):526–536

    Article  PubMed  Google Scholar 

  14. Rodriguez-Rodriguez L, Lopez-Mejias R, Fernandez-Gutierez B, Balsa A, Gonzales-Gay MA, Martin J (2015) Rheumatoid arthritis: genetic variants as biomarkers of cardiovascular disease. Curr Pharm Des 21(2):182–201

    Article  CAS  PubMed  Google Scholar 

  15. Kumar N, Marshall NJ, Hammal DM, Pearce MS, Parker L, Furniss SS et al (2007) Causes of death in patients with rheumatoid arthritis: comparison with siblings and matched osteoarthritis controls. J Rheumatol 34:1695–1698

    PubMed  Google Scholar 

  16. Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors and the effects of anti tumor necrosis factor therapy. Am J Med 116:305–311

    Article  PubMed  Google Scholar 

  17. McCoy SS, Crowson CS, Maradit-Kremers H, Therneau TM, Roger V, Matteson EL, Gabriel SE (2013) Long-term outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. J Rheumatol 40(5):605–610. doi:10.3899/jrheum.120941

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rostom S, Mengat M, Lahlou R, Hari A, Bahim R, Hassouni NH (2013) Metabolic syndrome in rheumatoid arthritis: case control study. BMC Musculosceletal Dis 14:147

    Article  Google Scholar 

  19. Parra-Salcedo F, Contreras-Yáñez I, Elías-López D, Aguilar-Salinas CA, Pascual-Ramos V (2015) Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity. Arthritis Res Ther 17:34. doi:10.1186/s13075-015-0549-x

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lee SH, Choi H, Cho BL, An AR, Seo YG, Jin HS et al (2016) Relationship between metabolic syndrome and rheumatoid arthritis. Korean J Fam Med 37(1):44–50. doi:10.4082/kjfm.2016.37.1.44

    Article  PubMed  PubMed Central  Google Scholar 

  21. Zhang J, Fu L, Shi J, Chen X, Li Y, Ma B, Zhang Y (2013) The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One 8(10):e78151. doi:10.1371/journal.pone.0078151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jiang P, Li H, Li X (2015) Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol 33:115–121

    PubMed  Google Scholar 

  23. Lu MC, Yan ST, Yin WY, Koo M, Lai NS (2014) Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study. PLoS One 9(7):e101528. doi:10.1371/journal.pone.0101528

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ursini F, Russo E, D’Angelo S, Arturi F, Hribal ML, D’Antona L et al (2016) Prevalence of undiagnosed diabetes in rheumatoid arthritis: an OGTT study. Medicine (Baltimore) 95(7):e2552. doi:10.1097/MD.0000000000002552

    Article  CAS  Google Scholar 

  25. Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA (2015) The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 10(2):e0117952. doi:10.1371/journal.pone.0117952

    Article  PubMed  PubMed Central  Google Scholar 

  26. Gabriel SE, Crowson CS, O’Fallon WM (1999) Comorbidity in arthritis. J Rheumatol 26:2475–2479

    CAS  PubMed  Google Scholar 

  27. Dessein PH, Stanwix AE, Joffe BI (2002) Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 4(5):R5

    Article  PubMed  PubMed Central  Google Scholar 

  28. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303–1309

    Article  PubMed  Google Scholar 

  29. Yang X, Gao F, Liu Y (2015) Association of homocysteine with immunological-inflammatory and metabolic laboratory markers and factors in relation to hyperhomocysteinaemia in rheumatoid arthritis. Clin Exp Rheumatol 33(6):900–903

    CAS  PubMed  Google Scholar 

  30. Hamamoto K, Yamada S, Yasumoto M, Yoda M, Yoda K, Tsuda A et al (2016) Association of nocturnal hypertension with disease activity in rheumatoid arthritis. Am J Hypertens 29(3):340–347. doi:10.1093/ajh/hpv119

    PubMed  Google Scholar 

  31. Zhao Q, Hong D, Zhang Y, Sang Y, Yang Z, Zhang X (2015) Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 94(14):e731. doi:10.1097/MD.0000000000000731

    Article  CAS  Google Scholar 

  32. Jonsson SW, Backman C, Johnson O, Karp K, Lundstrom E, Sundqvist KG, Dahlqvist SR (2011) Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 28:2597–2602

    Google Scholar 

  33. Sakai R, Hirano F, Kihara M, Yokoyama W, Yamazaki H, Harada S et al (2015) High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database. Mod Rheumatol 14:1–7

    Google Scholar 

  34. Myasoedova E, Gabriel SE, Green AB, Matteson EL, Crowson CS (2013) Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study. Arthritis Care Res (Hoboken) 65(10):1592–1599

    CAS  Google Scholar 

  35. Provan SA, Semb AG, Hisdal J, Stranden E, Aqewall S, Dagfinud H et al (2011) Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 70:812–817

    Article  PubMed  Google Scholar 

  36. Hurt-Camejo E, Paredes S, Masana L, Camejo G, Sartipy P, Rosengren B et al (2001) Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 44:2761–2767

    Article  CAS  PubMed  Google Scholar 

  37. Chavan VU, Ramavataram D, Patel PA, Rupani MP (2015) Evaluation of serum magnesium, lipid profile and various biochemical parameters as risk factors of cardiovascular diseases in patients with rheumatoid arthritis. J Clin Diagn Res 9(4):BC01–BC05

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Liao KP, Liu J, Lu B, Solomon DH, Kim SC (2015) Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. Arthritis Rheumatol 67(8):2004–2010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Södergren A, Karp K, Bengtsson C, Möller B, Rantapää-Dahlqvist S, Wållberg-Jonsson S (2015) The extent of subclinical atherosclerosis is partially predicted by the inflammatory load: a prospective study over 5 years in patients with rheumatoid arthritis and matched controls. J Rheumatol 42(6):935–942

    Article  PubMed  Google Scholar 

  40. Ahmed A, Hollan I, Curran SA, Kitson SM, Riggio MP, Mikkelsen K et al. (2016) Rheumatoid arthritis patients have a pro-atherogenic cytokine microenvironment in the aortic adventitia. Arthritis Rheumatol. doi: 10.1002/art.39574

  41. del Rincón I, Polak JF, O’Leary DH, Battafarano DF, Erikson JM, Restrepo JF et al (2015) Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis 74(6):1118–1123

    Article  PubMed  Google Scholar 

  42. Kuo D, Crowson CS, Gabriel SE, Matteson EL (2014) Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis. Int J Rheumatol 2014:523897. doi:10.1155/2014/523897

    Article  PubMed  PubMed Central  Google Scholar 

  43. Maijer KI, Neumann E, Müller-Lander U, Drop DACAD, Ramwadhdoeve TH, Choi IYK et al (2015) Serum Vaspin levels are associated with the development of clinically manifest arthritis in autoantibody-positive individuals. PLoS One 10(12):e0144932

    Article  PubMed  PubMed Central  Google Scholar 

  44. Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE (2006) Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 54(1):60–67

    Article  PubMed  Google Scholar 

  45. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE (2005) The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52(2):412–420

    Article  PubMed  Google Scholar 

  46. Schau T, Gottwald M, Arbach O, Seifert M, Schopp M, Neuss M et al (2015) Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J Rheumatol 42:2029–2037

    Article  CAS  PubMed  Google Scholar 

  47. Guedes C, Bianchi-Fior P, Cormier B, Barthelemy B, Rat AC, Boissier MC (2001) Cardiac manifestation of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum 45(2):129–135

    Article  CAS  PubMed  Google Scholar 

  48. Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM 3rd, Roger VL et al (2011) The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 38(8):1601–1606

    Article  PubMed  PubMed Central  Google Scholar 

  49. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A (2008) Does tumor necrosis factor-α inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667–677

    Article  CAS  PubMed  Google Scholar 

  50. Sarzi-Puttini P, Atzueni F, Doria A, Iaccarino L, Turiel M (2005) Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 14(9):780–784

    Article  CAS  PubMed  Google Scholar 

  51. Roldan AC, DeLong C, Qualls CR, Crawford MC (2007) Characterization of valvular heart disease in rheumatoid arthritis by transesophageal echocardiography and clinical correlates. Am J Cardiol 100:496–502

    Article  PubMed  Google Scholar 

  52. Giles JT, Fert-Bober J, Park JK, Bingham CO 3rd, Andrade F, Fox-Talbot K et al (2012) Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther 14:R39

    Article  PubMed  PubMed Central  Google Scholar 

  53. Di Franco M, Paradiso M, Mammarella A, Paoletti V, Labbadia G, Coppotelli L et al (2000) Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis 59:227–229

    Article  PubMed  Google Scholar 

  54. Liang KP, Myasoedova E, Crowson CS, Davis JM, Roger VL, Karon BL et al (2010) Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis 69(9):1665–1670

    Article  PubMed  PubMed Central  Google Scholar 

  55. Tomáš L, Lazúrová I, Oetterová M, Pundová L, Petrášová D, Studenčan M (2013) Left ventricular morphology and function in patients with rheumatoid arthritis. Wien Klin Wochenschr 125(9-10):233–238

    Article  PubMed  Google Scholar 

  56. Sakthiswary R, Das S (2015) Predictors of diastolic dysfunction in rheumatoid arthritis. Saudi Med J 36(5):525–529

    Article  PubMed  PubMed Central  Google Scholar 

  57. Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Huighes EA et al (2006) Left ventricular systolic dysfunction in rheumatoid disease. An unrecognized burden? J Am Coll Cardiol 47:1169–1174

    Article  PubMed  Google Scholar 

  58. Cioffi G, Viapiana O, Ognibeni F, Dalbeni A, Gatti D, Adami S et al (2015) Prevalence and factors related to left ventricular systolic dysfunction in asymptomatic patients with rheumatoid arthritis. A prospective tissue Doppler echocardiography study. Herz 40(7):989–996

    Article  PubMed  Google Scholar 

  59. Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M, Laghi-Pasini F (2014) Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev 13(9):936–944

    Article  PubMed  Google Scholar 

  60. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Svendsen JH et al (2012) Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 344:e1257

    Article  PubMed  PubMed Central  Google Scholar 

  61. Solus J, Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A et al (2008) Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 58:2662–2669

    Article  PubMed  PubMed Central  Google Scholar 

  62. Yxfeldt A, Wallberg-Jonsson S, Hultdin J, Rantapää-Dahlqvist S (2003) Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol 32:205–210

    Article  CAS  PubMed  Google Scholar 

  63. Bozkurt B, Mann DL, Deswal A (2009) Biomarkers of inflammation in heart failure. Heart Fail Rev 15(4):331–341

    Article  Google Scholar 

  64. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C et al (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102(25):3060–3067

    Article  CAS  PubMed  Google Scholar 

  65. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055–2059

    Article  CAS  PubMed  Google Scholar 

  66. Bozkurt B, Torre-Amione G, Smith Warren M, Soran OZ, Feldman AM, Mann DL (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Am J Assoc 103:1044–1047

    CAS  Google Scholar 

  67. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107:3133–3140

    Article  CAS  PubMed  Google Scholar 

  68. Coletta AP, Clark AL, Banarjee P, Cleland JG (2002) Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 4:243–247

    Article  Google Scholar 

  69. Gabriel SE (2008) Tumor necrosis factor inhibition: a part of the Solution or a part of the problem of heart failure in rheumatoid arthritis. Arthritis Rheum 58:637–640

    Article  PubMed  Google Scholar 

  70. Khanna D, McMahon M, Furst DE (2004) Anti tumor necrosis factor-α therapy and heart failure. Arthritis Rheum 50:1040–1048

    Article  CAS  PubMed  Google Scholar 

  71. Kotyla PJ, Owczarek A, Rakoczy J, Lewicki M, Kucharz EJ, Emery P (2012) Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin-1, interleukin 6 and NT-probrain natriuretic peptide. J Rheumatol 39:4701–4706

    Article  Google Scholar 

  72. Tomáš L, Lazúrová I, Pundová L, Oetterová M, Zakuciová M, Petrášová D, Studenčan M (2013) Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Clin Rheumatol 32(1):61–66

    Article  PubMed  Google Scholar 

  73. Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D et al (2007) Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-α antagonists. Rheumatol 46:1688–1693

    Article  CAS  Google Scholar 

  74. Al-Aly Z, Pan H, Zeringue A, Xian H, McDonald JR, El-Achkar TM, Eisen S (2011) Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res 157:10–16

    Article  CAS  PubMed  Google Scholar 

  75. Santos RC, Figueiredo VN, Martinz LC, Haro Moraes C, Quinaglia T, Boer-Martins L et al (2012) Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Rev Assoc Med Bras 58:698–702

    Article  PubMed  Google Scholar 

  76. Peters MJ, Welsh P, McInnes IB, Wolbink G, Dijkmans BA, Sattar N, Nurmohamed MT (2010) Tumour necrosis factor alpha blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 69(7):1281–1285

    Article  CAS  PubMed  Google Scholar 

  77. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt M, Levin R et al (2008) Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 156:336–341

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Solomon DH, Rassen JA, Kuriva B, Chen L, Harrold LR, Graham DJ et al (2013) Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis 72:1813–1818

    Article  CAS  PubMed  Google Scholar 

  79. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 16(2):CD008794

    Google Scholar 

  80. Suzuki A, Tamamura T, Okai T (2014) Five-year administration of tocilizumab to a patient with rheumatoid arthritis complicated by severe chronic heart failure. Jpn J Clin Immunol 37(6):488–492

    Article  CAS  Google Scholar 

  81. Kobayashi Y, Kobayashi H, Giles JT, Hirano M, Nakajima Y, Takei M (2015) Association of tocilizumab with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Int J Rheum Dis. doi: 10.1111/1756-185X.12632

  82. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T et al (2008) Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117:2662–2669

    Article  CAS  PubMed  Google Scholar 

  83. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M et al (2009) Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart 95:1502–1507

    Article  CAS  PubMed  Google Scholar 

  84. Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P et al (2014) Increased benefit of Interleukin -1 inhibition on vascular function, myocardial deformation and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging 7:619–628

    Article  PubMed  Google Scholar 

  85. Fleischamnn RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J et al (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist, (r-metHuIL-1ra) in patients with rheumatoid arthritis. Arthritis Rheumatism 48:927–934

    Article  Google Scholar 

  86. Abbate A, Van Tassel BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spilmann DW et al (2013) Effects of Interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction (from the Virginia commonwealth University-Anakinra remodeling Trial (2)(VCU-ART2) pilot study). J Cardiol 111:1394–1400

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department od Internal Medicine, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 040 11, Košice, Slovakia

    Ivica Lazúrová & Ľubomír Tomáš

Authors
  1. Ivica Lazúrová
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ľubomír Tomáš
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivica Lazúrová.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lazúrová, I., Tomáš, Ľ. Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment. Clinic Rev Allerg Immunol 52, 323–332 (2017). https://doi.org/10.1007/s12016-016-8566-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-016-8566-3

Keywords

Search

Navigation